KindredBio Announces Filing of an Investigational New Animal Drug Application for KIND-002

KIND-002 is expected to be a major new therapy for severe cutaneous diseases in dogs​

SAN FRANCISCO, California. (February 3, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today the filing of an Investigational New Animal Drug Application (INAD) with the U.S. Food and Drug Administration (FDA) for KIND-002. KIND-002 is a potent molecule being developed for severe dermatological diseases in dogs.

“We are very pleased to file our second INAD. KIND-002 is a very promising molecule, targeting serious dermatological diseases in dogs. We believe that it will demonstrate substantial and major clinical benefit, with significantly improved safety profile compared to the current treatment options. We look forward to advancing it for the benefit of numerous dogs with great unmet medical needs.” stated Richard Chin, Chief Executive Officer of KindredBio. “This marks another major milestone for KindredBio, and continues to build our track record of executing with high standards and to rapid timelines.”

About KindredBio
“Best Medicines for Our Best Friends”
www.kindredbio.com

KindredBio is a leading veterinary biotechnology company, focused on developing breakthrough therapies for dogs, cats, and horses. Founded by industry veterans formerly from Genentech and Elan Pharmaceuticals who have experience developing antibody drugs such as Lucentis®, Tysabri®, Xolair®, and Rituxan®, Kindred Bio is committed to bringing the very best science and medicine to companion animals.

Forward-Looking Statements

Forward-looking statements in this news release involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in such forward-looking statements. These factors include, but are not limited to uncertainties associated with: drug development and regulatory review process, scientific discovery process, competition, pricing environment, financing, intellectual property, and evolution of the companion animal market. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date.

Trademark Acknowledgements

Lucentis® is a registered trademarks of Genentech, Inc. Rituxan® is a registered trademark of Biogen Idec Inc. Xolair® is a registered trademark of Novartis AG Corporation. Tysabri® is a trademark of Elan Pharmaceuticals, Inc.

Contact
Denise Bevers
KindredBio
denise.bevers@kindredbio.com.
(650) 701-7909